Medicare will now cover chimeric antigen receptor (CAR) T-cell therapies for eligible beneficiaries nationwide, the Centers for Medicare & Medicaid Services (CMS) recently announced.
Over the last 2 years, the US Food and Drug Administration (FDA) approved 2 CAR T-cell therapies to treat some patients with certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia.
Rubin R. Medicare to Cover CAR T-Cell Therapies. JAMA. 2019;322(12):1133. doi:10.1001/jama.2019.14752
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: